AC Immune to Present at Jefferies 2019 London Healthcare Conference
Prof.
Jefferies 2019 London Healthcare Conference
Date: November 21, 2019 | 5:20 pm GMT
Format: Fireside chat
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune
A webcast of the presentation will be available on the Events Page of AC Immune’s website and at the Jefferies 2018 Healthcare Conference website and will be active for 90 days following the event.
About
As a strategic leader in the field of neurodegenerative diseases,
For further information, please contact:
Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 646 876 5538 E-mail: joshua.drumm@acimmune.com |
U.S. Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 E-mail: kgallagher@lavoiehealthscience.com |
Head of Global Communication Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com |
European Investors Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 E-mail: chris@lifesciadvisors.com |
Forward-looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information—Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA